Enterococcus News and Research

RSS

MRSA survivors unite across the globe to raise awareness and educate public on prevention

MRSA Survivors Network with MRSA survivors, family members and other victims of healthcare-acquired infections unite across the globe and on World MRSA Day, October 2, 2010 in a grassroots movement to raise awareness and push for more mandated reporting of infections, MRSA screening laws, funds to raise awareness and educate the public on prevention, which will save lives.

15 Jun 2010

Kansas State University researcher awarded NIH grant to study antibiotic-resistant bacteria

Antibiotic-resistant bacteria are becoming a growing problem around the world, and are a particular worry in hospital-acquired infections.

20 May 2010

Cempra Pharmaceuticals announces schedule of poster presentations at ECCMID 2010

Cempra Pharmaceuticals today announced its schedule of poster presentations at the 20th European Congress of Clinical Microbiology and Infectious Disease (ECCMID) in Vienna, Austria, on April 10-13, 2010.

8 Apr 2010

Cepheid to launch GeneXpert Infinity-48 in Europe at 20th ECCMID

Cepheid will initiate European launch of its newest addition to the GeneXpert® family of molecular diagnostic testing systems, the GeneXpert Infinity-48, at the 20th annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Vienna, Austria. The GeneXpert Infinity-48 System is the world's first and only fully-automated, random-access system designed for management of the entire molecular testing workflow — from sample data, cartridge loading and unloading, to final reporting of test results and disposal of cartridges.

7 Apr 2010

Bactericidal antibiotic with activity against MRSA for treatment of cSSSIs would earn 25% patient share: Report

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a therapy's effect on overall clinical success is the attribute that most influences surveyed infectious disease specialists' prescribing decisions in the treatment of complicated skin and skin structure infections (cSSSIs).

19 Mar 2010

MicuRx Pharmaceuticals files IND for MRX-I antibiotic drug candidate with Chinese SFDA

MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced that it has filed an Investigational New Drug (IND) application with the State Food and Drug Administration (SFDA) in China for MRX-I, its first development-stage antibiotic drug candidate. MRX-I, an orally-administered oxazolidinone, targets multi-drug resistant Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).

15 Mar 2010

bioMerieux introduces FDA cleared chromID VRE for detecting Enterococcus faecium and Enterococcus faecalis

bioMerieux – a world leader in the field of in vitro diagnostics – today announced the launch of the first Food and Drug Administration (FDA) cleared chromID™ VRE, a simple and cost-effective solution in the struggle against vancomycin-resistant enterococci (VRE). chromID VRE is the first to receive an FDA 510(k) clearance for the qualitative detection of Enterococcus faecium and Enterococcus faecalis showing acquired resistance to vancomycin in stool specimens.

12 Mar 2010

Ecolab launches EnCompass Environmental Hygiene program to improve patient room hygiene

Ecolab Inc. today announced the launch of its new EnCompass™ Environmental Hygiene program, a comprehensive clinical program that helps hospitals improve patient room hygiene and prevent the spread of infections.

1 Feb 2010

Lakeshore General Hospital restricts patient visits as a result of bacterial outbreak

Lakeshore General Hospital, a West Island HSSC facility, is restricting patient visits in the 4-West medical unit as a result of a bacterial outbreak. Other services provided by this hospital centre will not be affected. This preventive measure will remain in place until January 5.

30 Dec 2009

Malaria nasal vaccine, antimicrobial peptide against MRSA, and safer method to prolong orange juice shelf life

An experiemental nasally administered malaria vaccine prevented parasite transmission from infected mice to mosquitoes and could play an important role in the fight against human malaria. The researchers from Japan report their findings in the December 2009 issue of the journal Infection and Immunity.

19 Dec 2009

bioMerieux announces the upcoming availability of ABxAlert from ICNet International

bioMerieux, a world leader in the field of in vitro diagnostics, announced the upcoming availability of ABxAlert® from ICNet International Ltd., a global clinical informatics company, at the 44th American Society of Health-System Pharmacists Midyear Clinical Meeting and Exhibition.

8 Dec 2009

Two antimicrobial drug developing companies evaluate new approach for treating bacterial infections

Chaperone Technologies, Inc. and MerLion Pharmaceuticals Pte Ltd., both privately-held companies developing new antimicrobial drugs, announced today that they are together evaluating a unique approach for the treatment of resistant and life-threatening bacterial infections.

4 Dec 2009

BD acquires HandyLab for $275 million

BD today announced the completion of its acquisition of HandyLab, Inc., an Ann Arbor, Michigan-based company that develops and manufactures molecular diagnostic assays and automation platforms.

From BD (Becton, Dickinson and Company) 20 Nov 2009

SDC-based hard surface disinfectant is effective against the 2009 H1N1

PURE Bioscience, creators of the patented silver dihydrogen citrate (SDC) antimicrobial, announced today that its SDC-based hard surface disinfectant is effective against the 2009 H1N1 and is included on the list published by the U.S. Environmental Protection Agency (EPA) of antimicrobial products effective against the 2009 H1N1 flu strain based on their effectiveness against other influenza A virus strains.

27 Oct 2009

BD to acquire HandyLab

BD (Becton, Dickinson and Company)announced today that it signed a definitive agreement to acquire HandyLab, Inc., an Ann Arbor, Michigan-based company that develops and manufactures molecular diagnostic assays and automation platforms. The acquisition is subject to regulatory approvals and is expected to close during the first quarter of fiscal year 2010. The financial terms of the agreement were not disclosed.

From BD (Becton, Dickinson and Company) 24 Oct 2009

Study on the economic impact of antibiotic overuse and antibiotic-resistant infections

The Alliance for the Prudent Use of Antibiotics (APUA) and Cook County Hospital (currently John H. Stroger, Jr. Hospital of Cook County), today announced the release of an eye-opening study on the economic impact of antibiotic overuse and antibiotic-resistant infections (ARIs) sponsored by an unrestricted educational grant from bioMerieux and the Centers for Disease Control and Prevention (CDC).

19 Oct 2009

TAXIS Pharmaceuticals, Rutgers and UMDNJ to develop and commercialize a novel antimicrobial technology

TAXIS Pharmaceuticals, Inc. (TAXIS), Rutgers, The State University of New Jersey, and the University of Medicine and Dentistry of New Jersey (UMDNJ) have entered into an exclusive licensing agreement for worldwide rights to develop and commercialize a novel antimicrobial technology addressing multidrug-resistant (MDR) bacterial infections.

14 Oct 2009

Paratek Pharmaceuticals and Novartis to collaborate in PTK 0796 broad-spectrum antibiotic development

Paratek Pharmaceuticals, Inc. announced today that it has entered into an exclusive worldwide collaborative development, manufacturing and commercialization license agreement with Novartis for Paratek's lead broad-spectrum antibiotic, PTK 0796, a first-in-class aminomethylcycline (AMC) in Phase 3 clinical trials.

8 Oct 2009

Report on the worldwide market for anti-infectives

Drug resistance is a key public health problem and also a problem for makers of branded antibacterial products, according to the findings of a new report. Traditional antibiotics: quinolones, cephalosporins, and penicillins, have seen their market share erode due to loss of effectiveness, while at the same time they are facing heavy generic competition.

3 Oct 2009

E. coli pervasive in stream-water with fecal indicator bacteria

Bacteria commonly used to indicate health risks in recreational waters might not be so reliable after all. Pathogenic E. coli were pervasive in stream-water samples with low concentrations of fecal indicator bacteria.

23 Sep 2009